Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus
ACS Pharmacology & Translational Science · 09.06.2023 · 6 (6) · 857-867
DOI: 10.1021/acsptsci.2c00180 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 22.05.2023. Verfasst von Fabiana Renzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics, Università di Roma "La Sapienza", 00185 Rome, Italy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Entry inhibitors are an important resource in the response against emerging pathogens like the novel SARS-CoV-2, which enters human cells via interaction between the surface spike glycoprotein and the cellular membrane receptor angiotensin-converting enzyme 2 (ACE2). Using a combination of comparative structural analyses of the binding surface of the spike to ACE2, docking experiments, and molecular dynamics simulations, we identified a stable fragment of ACE2 that binds to the spike, is soluble, and is not predicted to bind to its physiological ligand angiotensin II. From this fragment we computationally designed and experimentally validated a smaller, stable peptide that disrupts ACE2-spike interaction at nanomolar concentrations, suggesting its potential use as a decoy that could interfere with viral binding by competition.
Autor:innen und Institutionen
- Department of Physics, Università di Roma "La Sapienza", 00185 Rome, Italy.
- School of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, Nebraska 68182, USA.
- Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68182, USA.
- Department of Pharmacology & Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68182, USA.
ORCID-Profile: Siddappa N Byrareddy, Dario Ghersi
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- National Institute of Allergy and Infectious Diseases
- University of Nebraska Omaha
- National Institute on Drug Abuse
- COVID-19 Rapid Response
- University of Nebraska System
Zitieren
APA
Renzi, F., Seamann, A., Ganguly, K., Pandey, K., Byrareddy, S. N., Batra, S., Kumar, S., & Ghersi, D. (2023). Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. ACS Pharmacology & Translational Science, 6(6), 857-867. https://doi.org/10.1021/acsptsci.2c00180
Vancouver
Renzi F, Seamann A, Ganguly K, Pandey K, Byrareddy SN, Batra S, et al. Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. ACS Pharmacology & Translational Science. 2023;6(6):857-867. doi:10.1021/acsptsci.2c00180
BibTeX
@article{Renzi2023,
author = {Renzi, Fabiana and Seamann, Austin and Ganguly, Koelina and Pandey, Kabita and Byrareddy, Siddappa N and Batra, Surinder and Kumar, Sushil and Ghersi, Dario},
title = {Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus},
journal = {ACS Pharmacology & Translational Science},
year = {2023},
volume = {6},
number = {6},
pages = {857--867},
doi = {10.1021/acsptsci.2c00180}
}
EUVIMED